• 

  “㈜미림진, ㈜보령과 혁신신약 개발분야 업무 협약(MOU) 체결” / MirimGENE and BORYUNG signed an MOU in the field for innovative new drug development

  POSTED ON March 13, 2024

  ㈜미림진(대표 진미림)은 ㈜보령(대표 장두현)과 혁신신약 개발 분야 업무제휴 협약(MOU)을 체결했다고 13일 밝혔다.   ㈜미림진과 ㈜보령은 이번 전략적 업무 제휴를 바탕으로 난치성 면역 질환 혁신 신약과 제약산업 경쟁력 강화를 위해 양사의 협력을 도모할 예정이다.    &...

  READ MORE
• 

  미림진, 패혈증 테라노스틱스 연구결과 글로벌 학술지 게재 / MirimGENE, Sepsis Theranostics research results published in global academic journals

  POSTED ON December 18, 2023

  We expect to present an innovative alternative that can increase the survival rate of septic shock.” Mirim Jin (CEO MirimGENE) announced on the 18th that the results of sepsis theranostics targeting WARS1 were published in the world-renowned medical journal 'EMBO Molecular Medicine (IF=14.005)' (title: 'Highly secreted tryptophanyl-tRNA synthetase as...

  READ MORE
• 

  미림진, 진미림 대표 여성생명과학기술포럼 심포지엄 강연 / MirimGENE’ CEO, 22nd Women’s Bioscience Forum Symposium Presentation

  POSTED ON September 21, 2023

  Dr. Mirim Jin, the CEO, was in attendance at the Women’s Bioscience Forum (WBF) Symposium (22nd), which took place on September 21st, and delivered a presentation.   

  READ MORE
• 

  미림진, "WARS1 타깃 자가면역질환 치료제 개발…내년 하반기 비임상 진입" / MirimGENE "Development of WARS1-targeted autoimmune disease therapy, launch of pre-clinical trials in the second half of next year."

  POSTED ON August 17, 2023

  CEO Mirim Jin conducted an interview with HitNews on the topic of “MirimGENE's core pipeline status and future blueprint.""We will leap forward as a biotech that leads the development of innovative new drugs (first-in-class) that can save the lives of autoimmune disease patients around the world. Currently, the manufacturing process (CMC) stage of the lead pipeline (new drug candida...

  READ MORE
• 

  미림진, BIO USA 2023 참가 / MirimGENE, at BIO USA 2023

  POSTED ON June 15, 2023

  MirimGENE attended BIO USA 2023 in Boston from June 5th to 8th and was chosen as the presenting company at BIO USA 2023.MirimGENE was also able to connect with numerous global companies such as Novartis, Merck, Pfizer and present our science and technology to them.   

  READ MORE